PTJ
HRMY icon

Paul Tudor Jones’s Harmony Biosciences HRMY Stock Holding History

Paul Tudor Jones’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,534
Closed -$1.08M – 3880
2026
Q1 		$1.08M Buy
38,534
+9,732
+34% +$319K ﹤0.01% 2318
2025
Q4 		$1.08M Buy
+28,802
New +$947K ﹤0.01% 2218
2024
Q1 		– Sell
-32,273
Closed -$1.04M – 2448
2023
Q4 		$1.04M Buy
+32,273
New +$901K 0.01% 1422
2023
Q3 		– Sell
-30,142
Closed -$1.06M – 2532
2023
Q2 		$1.06M Buy
30,142
+371
+1% +$12.8K 0.01% 1286
2023
Q1 		$972K Buy
+29,771
New +$1.36M 0.02% 1224
2020
Q4 		– Sell
-6,236
Closed -$211K – 1448
2020
Q3 		$211K Buy
+6,236
New +$227K 0.01% 1124

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's HRMY Position: Q2 2026 in Review

Paul Tudor Jones sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 38,534 shares — an estimated $1.08M sold.

Paul Tudor Jones first reported a position in HRMY in Q3 2020 and held it in 6 quarters. The position peaked at $1.08M in Q1 2026. 324 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Paul Tudor Jones reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 38,534 Harmony Biosciences shares in Q2 2026, an estimated $1.08M.
  • Paul Tudor Jones first reported a position in Harmony Biosciences in Q3 2020 and held it in 6 quarters.
  • Paul Tudor Jones's Harmony Biosciences position peaked at $1.08M in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.